Goussetis et al. first reported the autophagic degradation of the BCR-ABL oncoprotein in CML cells under arsenic trioxide (ATO) treatment in 2012 [282]. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.